|
Patent landscape, scope, and claims: |
United States Patent 6,844,008: Scope, Claims, and Landscape Analysis
United States Patent 6,844,008, granted on January 18, 2005, to Pfizer Inc., covers the compound known as Celecoxib, marketed as Celebrex, and its pharmaceutical compositions for treating inflammatory conditions. The patent's scope is primarily directed at the compound itself and its use in ameliorating pain and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The issued claims focus on the specific chemical structure of Celecoxib and methods of treating these diseases. The patent landscape reveals extensive subsequent litigation and the emergence of generic competition following its expiration.
What Does United States Patent 6,844,008 Claim?
Patent 6,844,008 contains multiple claims defining the scope of its protection. The core claims are directed towards the Celecoxib compound and its therapeutic applications.
Key Claims Analysis
-
Claim 1: This is a primary independent claim defining the compound 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. This claim specifically recites the chemical structure of Celecoxib, establishing its novelty and inventiveness. The claim also includes salts and hydrates of this compound.
-
Claim 2: This claim recites a pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier. This broadens protection to include formulations of the active pharmaceutical ingredient (API), which is standard for drug patents.
-
Claims 3-9: These claims further define pharmaceutical compositions, specifying various combinations with other active ingredients or excipients, and detailing specific methods of formulation, such as oral administration.
-
Claims 10-23: These claims focus on methods of treatment. They describe methods for treating pain, inflammation, fever, and arthritic conditions by administering an effective amount of the compound of claim 1 to a subject in need thereof. Specific conditions mentioned include osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, primary dysmenorrhea, and gout.
-
Claims 24-25: These claims relate to a method of reducing synovial fluid prostaglandin E2 levels and a method of inhibiting cyclooxygenase-2 (COX-2) enzyme activity, both by administering the claimed compound. These claims highlight the mechanism of action.
Technical Specificity and Limitations
The patent is highly specific in its chemical definition of Celecoxib. The inclusion of "salts and hydrates" provides some latitude, but the core structure is rigidly defined. The "effective amount" language in the treatment claims is a standard pharmaceutical patent term, requiring demonstration of efficacy at a given dosage, but it does not specify a precise dosage range within the claims themselves. The patent does not claim the synthesis method of Celecoxib, nor does it claim specific polymorphs or crystalline forms, which are often subjects of later patents.
What is the Scope of Protection Afforded by Patent 6,844,008?
The scope of Patent 6,844,008 extends to the Celecoxib molecule itself, its pharmaceutical compositions, and its use in treating a defined set of inflammatory and pain-related conditions.
Key Areas of Protection
-
The API: The patent directly protects the chemical entity 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. Any party making, using, selling, or importing this specific chemical compound in the United States would infringe, subject to patent expiration.
-
Pharmaceutical Formulations: Compositions containing Celecoxib mixed with pharmaceutically acceptable carriers are covered. This prevents competitors from marketing generic versions without infringing the patent.
-
Therapeutic Uses: The patent claims specific methods of using Celecoxib to treat pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, primary dysmenorrhea, and gout. This means generic manufacturers cannot market their Celecoxib products for these specific approved indications until the patent expires.
Geographic and Temporal Limitations
-
Jurisdiction: Protection is limited to the United States, as it is a U.S. patent.
-
Duration: The patent was granted on January 18, 2005. As an original patent term, it would have expired 20 years from its filing date. The U.S. filing date for this patent was July 2, 1998. Therefore, the original expiration date was July 2, 2018. Patent term adjustments or extensions due to regulatory review (e.g., Hatch-Waxman Act) could have modified this date, but the core protection for the compound and its primary uses has concluded.
Exclusions and Potential Gaps
The patent does not claim:
-
Manufacturing Processes: Specific synthetic routes or purification methods are not claimed. This can allow for the development of alternative, non-infringing manufacturing processes by generic competitors once the core compound patent expires.
-
Specific Formulations or Dosages (beyond general composition): While pharmaceutical compositions are claimed, novel formulations or specific dosage regimens might be eligible for separate patent protection.
-
Off-Label Uses: Uses for conditions not explicitly claimed in the patent are not protected by this patent.
What is the Patent Landscape for Celecoxib and Related Technologies?
The patent landscape surrounding Celecoxib is characterized by a series of patents covering the compound, its synthesis, formulations, and therapeutic uses, followed by extensive patent litigation and the eventual rise of generic competition.
Key Patent Families and Filings
-
Core Compound Patents: The foundational protection for Celecoxib, including Patent 6,844,008, was established through a series of applications filed in the late 1990s.
-
Process Patents: Pfizer and other entities have filed patents related to specific methods of synthesizing Celecoxib, aiming to optimize yield, purity, or cost-effectiveness. These patents can extend market exclusivity even after the primary compound patent expires. Examples include patents covering polymorphic forms or specific crystallization techniques.
-
Formulation Patents: Patents have been filed for novel formulations of Celecoxib, such as extended-release versions or combination therapies with other drugs. These are critical for maintaining market share and extending the product lifecycle.
-
Method of Use Patents: Beyond the initial indications, further research may have led to patents for using Celecoxib to treat other conditions or for specific patient populations.
Litigation and Generic Entry
-
Patent Challenges: Upon approaching expiration, generic manufacturers frequently challenge existing patents through Paragraph IV certifications under the Hatch-Waxman Act. This often involves litigation asserting that the generic product does not infringe the remaining valid patents or that the patents are invalid.
-
Infringement Lawsuits: Pfizer, as the patent holder, has initiated infringement lawsuits against generic companies seeking to launch their versions of Celecoxib. The outcomes of these lawsuits depend on the specific claims being litigated and the validity of the patents in question.
-
Generic Approvals: The U.S. Food and Drug Administration (FDA) approves generic versions of drugs after the relevant patents expire or are successfully challenged. The first generic versions of Celecoxib became available following the expiration of key patents.
Competitive Landscape and Market Dynamics
-
Branded vs. Generic: Before patent expiration, Pfizer held a monopoly on Celebrex. Post-expiration, the market sees competition between branded Celebrex and multiple generic Celecoxib products.
-
Market Share Shift: Generic entry typically leads to a significant decrease in the price of the drug and a shift in market share from the branded product to generics.
-
Intellectual Property Strategy: Pharmaceutical companies employ a multifaceted IP strategy, including filing patents on different aspects of a drug (compound, process, formulation, use), to maximize market exclusivity and revenue. This often involves a "patent thicket" where multiple overlapping patents protect a single drug.
Notable Developments
-
Early Patent Term Extensions: Drug patents are eligible for Patent Term Extensions (PTE) to compensate for regulatory review delays. Celecoxib would have received such an extension.
-
Exclusivity Periods: Beyond patent protection, the Hatch-Waxman Act provides periods of market exclusivity (e.g., 5 years for New Chemical Entities) which can further delay generic entry.
-
Ex-U.S. Patent Landscape: While this analysis focuses on the U.S., similar patent filings, litigation, and generic entries have occurred in other major markets, following their respective patent laws and regulatory frameworks.
Key Takeaways
- United States Patent 6,844,008 covers the chemical compound Celecoxib and its use in treating inflammatory and pain conditions.
- The patent's claims are specific to the chemical structure of Celecoxib and its administration for defined medical indications.
- The patent expired in July 2018, allowing for generic market entry.
- The patent landscape for Celecoxib includes numerous related patents on synthesis, formulations, and uses, which have been subject to extensive litigation.
- Generic competition for Celecoxib has been established following patent expiration and successful regulatory approvals.
Frequently Asked Questions
-
What specific chemical name is protected by United States Patent 6,844,008?
The patent protects 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
-
When did United States Patent 6,844,008 expire?
The original expiration date for United States Patent 6,844,008 was July 2, 2018, based on its filing date of July 2, 1998.
-
Does Patent 6,844,008 cover the manufacturing process for Celecoxib?
No, the patent does not claim the manufacturing process for Celecoxib; its claims are primarily directed at the compound itself and its therapeutic uses.
-
What are the main therapeutic uses claimed in Patent 6,844,001?
The patent claims methods for treating pain, inflammation, fever, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, primary dysmenorrhea, and gout.
-
Can generic versions of Celecoxib be sold in the United States?
Yes, generic versions of Celecoxib can be sold in the United States because the primary compound patent, United States Patent 6,844,008, has expired.
Citations
[1] Pfizer Inc. (2005). U.S. Patent No. 6,844,008. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
